SML3675

GSK1904529A

≥98% (HPLC)

• Sinónimos: GSK 1904529, GSK 1904529A, GSK 4529, GSK-1904529, GSK-1904529A, GSK-4529, GSK1904529, GSK4529, N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide
• Fórmula empírica (notación de Hill): C₄₄H₄₇F₂N₉O₅S
• Número de CAS: 1089283-49-7
• Peso molecular: 851.96
• MDL number: MFCD17010271
• UNSPSC Code: 12352200
• NACRES: NA.21

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (Warmed)
• storage temp.: -10 to -25°C
• SMILES string: Fc1c(c(ccc1)F)NC(=O)c2c(ccc(c2)c3nc4[n](c3c5nc(ncc5)Nc6c(cc(c(c6)CC)N7CCC(CC7)N8CCN(CC8)[S](=O)(=O)C)OC)cccc4)OC
• InChI key: MOSKATHMXWSZTQ-UHFFFAOYSA-N

Descripción

Biochem/physiol Actions

GSK1904529A is an orally active, potent and selective insulin-like growth factor-1 receptor and insulin receptor inhibitor (IGF-1R/IR IC50 = 27/25 nM; IC50 ≥3.2 μM/35 other kinases) that blocks cellular receptor autophosphorylation and downstream signaling. GSK1904529A inhibits IGF-1R-dependent proliferation in cancer cultures (IC50 in nM = 81-165/multiple myeloma, 35-62/Ewing′s sarcoma, 43/Askin’s tumor SK-N-MC, 104-124/colon cancer, 137-189/breast cancer) and suppresses the growth of human tumor xenografts in mice in vivo (30 mg/kg via qd. or bid. po.; HT29, BxPC3, COLO 205, NIH-3T3-LISN).

Orally active, potent and selective insulin-like growth factor-1 receptor (IGF-1R) & insulin receptor (InsR, IR) inhibitor in vitro and in vivo.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable